Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Cancer Patients 1Pancreatic Neoplasms 1Locally Advanced Rectal Cancer 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 58130-nm albumin-bound paclitaxel 34Specimen Handling 27Albumin-Bound Paclitaxel 23Fluorouracil 22Magnetic Resonance Spectroscopy 21Leucovorin 21Irinotecan 21Oxaliplatin 19Biopsy 17Taxes 16pembrolizumab 15Cisplatin 11Cyclophosphamide 10Cetuximab 9fludarabine 8Capecitabine 8durvalumab 7Radiosurgery 7Nivolumab 7Carboplatin 7irinotecan sucrosofate 6dehydroftorafur 6Pemetrexed 6olaparib 5Radiotherapy 5Ipilimumab 5Erlotinib Hydrochloride 5Blood Specimen Collection 5trastuzumab deruxtecan 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × camrelizumab × 90 days × Clear all
NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡